Popular
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 2
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 2
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual EventPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 3
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 3
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
CardiologySPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
Muthiah Vaduganathan, MD, MPH
Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
CME/CEChairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
Jean Hoffman-Censits, MD
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
CME/CEGrooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Pam R. Taub, MD, FACC, FASPC
Programs
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 4
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 4
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 3
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 3
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
CardiologySPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
Muthiah Vaduganathan, MD, MPH
Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
CME/CEChairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
Jean Hoffman-Censits, MD
The OD As a Salesperson + the Ocular Side of Oncology
Modern OptometryThe OD As a Salesperson + the Ocular Side of Oncology
Cecelia Koetting, OD, FAAO
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and HematologyDESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
Clinical Practice
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CETranslating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and HematologyTROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and HematologyDESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Movements With Meaning: Reading the Pattern, Not the Label
CME/CEMovements With Meaning: Reading the Pattern, Not the Label
Karen E. Anderson, MD
Hubert H. Fernandez, MD
How Real-World Adherence Is Shaping Preventive Migraine Treatment
NeuroFrontiersHow Real-World Adherence Is Shaping Preventive Migraine Treatment
Alexandria May, PharmD, BCPS
Jessica Ailani, MD, FAHS, FAAN, FANA
Sjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
CME/CESjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
Chadwick R. Johr, MD
Doctors Lounge
“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
The Convergence“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
Brian P. McDonough, MD, FAAFP
Rajiv Kumar, MD
Optimizing Medical Affairs Approaches with CME Best Practices
MAPSChatsOptimizing Medical Affairs Approaches with CME Best Practices
Matt Birnholz, MD
Karen Roy, MSc
Inside Medical Affairs: MSL Insights on AI, Strategy, and Impact
MAPSChatsInside Medical Affairs: MSL Insights on AI, Strategy, and Impact
Matt Birnholz, MD
Brandon Young, PhD
Collaboration in Medical Affairs: Increasing Value and Impact
MAPSChatsCollaboration in Medical Affairs: Increasing Value and Impact
Matt Birnholz, MD
Renu Juneja, PhD
Designing Smarter Insight Frameworks in Medical Affairs
MAPSChatsDesigning Smarter Insight Frameworks in Medical Affairs
Matt Birnholz, MD
Tony Page
The Changing Landscape of CRC Screening and Prevention
On the Frontlines of Colorectal CancerThe Changing Landscape of CRC Screening and Prevention
Ryan Quigley
Samuel Muench, MD
CME
Case Challenges in Systemic Mastocytosis: Clinical Insights From the Expert Roundtable
CME/CECase Challenges in Systemic Mastocytosis: Clinical Insights From the Expert Roundtable
Carole Bitar, MD, FAAD
Matthew P. Giannetti, MD
Benjamin Ungar, MD
Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
CME/CEPrecision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
Harry Erba, MD, PhD
Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
CME/CEChairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
Kathleen N. Moore, MD, MS
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal
Industry Feature
Is It Time to Rethink How We Support Depression Management?
Medical Industry FeatureIs It Time to Rethink How We Support Depression Management?
Charles Turck, PharmD, BCPS, BCCCP
Andrew J. Cutler, MD
Gustavo Alva, MD, DFAPA
Advancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
Medical Industry FeatureAdvancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
Jennifer Caudle, DO, FACOFP
Seth Wander, MD, PhD
Ocular Management in PROC: Insights on Collaborative Care Across Practice Settings
Project Oncology®Ocular Management in PROC: Insights on Collaborative Care Across Practice Settings
Jennifer Caudle, DO, FACOFP
Ida Micaily, MD
Jeffrey Varanelli, OD
The Corticosteroid Journey in PMR: Understanding the Patient Experience
Medical Industry FeatureThe Corticosteroid Journey in PMR: Understanding the Patient Experience
Charles Turck, PharmD, BCPS, BCCCP
Rodney Daniel, MD
Grace C Wright, MD, PhD, FACR
Quick Takes in ATTR-CM: Symptoms and Comorbidities
Medical Industry FeatureQuick Takes in ATTR-CM: Symptoms and Comorbidities
Joshua Mitchell, MD, FACC
BRCA and HRD Biomarker Testing in Advanced Ovarian Cancer: A KOL Panel Discussion
Medical Industry FeatureBRCA and HRD Biomarker Testing in Advanced Ovarian Cancer: A KOL Panel Discussion
Sharyn N. Lewin, MD, FACS, FACOG
Dana Chase, MD